Skp2-inhibitor-1-DataSheet-生命科學(xué)試劑-MCE_第1頁
Skp2-inhibitor-1-DataSheet-生命科學(xué)試劑-MCE_第2頁
Skp2-inhibitor-1-DataSheet-生命科學(xué)試劑-MCE_第3頁
Skp2-inhibitor-1-DataSheet-生命科學(xué)試劑-MCE_第4頁
全文預(yù)覽已結(jié)束

下載本文檔

版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)

文檔簡介

Hotline:400-820-3792Inhibitors ? ScreeningLibraries ? Proteinswww.MedChemESkp2inhibitor1Cat.No.:HY-149293CASNo.:2760612-63-1分子式:C??H??ClN?O分子量:406.91作用靶點(diǎn):E1/E2/E3Enzyme作用通路:MetabolicEnzyme/Protease儲(chǔ)存方式: 4°C,sealedstorage,awayfrommoistureandlightInsolvent:-80°C,6months;-20°C,1month(sealedstorage,awayfrommoistureandlight)溶解性數(shù)據(jù)體外實(shí)驗(yàn)DMSO:50mg/mL(122.88mM;Needultrasonic)SolventMass1mg5mg10mgConcentration制備儲(chǔ)備液1mM2.4575mL12.2877mL24.5755mL5mM0.4915mL2.4575mL4.9151mL10mM0.2458mL1.2288mL2.4575mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液;一旦配成溶液,請(qǐng)分裝保存,避免反復(fù)凍融造成的產(chǎn)品失效。儲(chǔ)備液的保存方式和期限:-80°C,6months;-20°C,1month(sealedstorage,awayfrommoistureandlight)。-80°C儲(chǔ)存時(shí),請(qǐng)?jiān)?個(gè)月內(nèi)使用,-20°C儲(chǔ)存時(shí),請(qǐng)?jiān)?個(gè)月內(nèi)使用。BIOLOGICALACTIVITY生物活性Skp2inhibitor1(compound14i)是一種Skp2抑制劑,干擾Skp2-Cks1相互作用,IC50為2.8μM。Skp2inhibitor1也具有抗癌活性[1]。IC50&TargetGrowtharrest-specificprotein6(Gas6)-CellCyclinKinaseSubunit1(Cks1)[1]IC50:2.8μM(Growtharrest-specificprotein6,Gas6;CellCyclinKinaseSubunit1,Cks1)[1]1/4 MasterofBioactiveMolecules—您身邊的抑制劑大師www.MedChemE體外研究Skp2inhibitor1(2.8μM,72h)interferestheSkp2?Cks1interaction,againstPC-3andMGC-803cellswithIC50valuesof4.8and7.0μM,respectively[1].Skp2inhibitor1(10μM,48h)inhibitstheproliferationandmigrationofPC-3andMGC-803cell,causingthemtoblockintheSphaseandpromotecellapoptosis[1].CellViabilityAssay[1]CellLine:PC-3,MGC-803Concentration:0-10μMIncubationTime:72hResult:AgainsttheSkp2?Cks1interactionwithanIC50valueof2.8μM,andagainstPC-3andMGC-803cellswithIC50valuesof4.8and7.0μM,respectively.ApoptosisAnalysis[1]CellLine:PC-3,MGC-803Concentration:2.5μM,5μM,10μMIncubationTime:0-48hResult:LeadedtocellcycleS-phasearrestinadose-dependentmanner,andinducedapoptosisinadose-dependentmanner,suchasnuclearfragmentation,condensation,andcellshrinkage.CellProliferationAssay[1]CellLine:PC-3,MGC-803Concentration:0.5μM,1μM,2μMIncubationTime:10daysResult:Inhibitedcolony-formingabilitiesinadose-dependentmanner.CellMigrationAssay[1]CellLine:PC-3,MGC-803Concentration:2.5μM,5μM,10μMIncubationTime:48hResult:Inhibitedmigrationinadose-dependentmanner.CellInvasionAssay[1]2/4 MasterofBioactiveMolecules—您身邊的抑制劑大師www.MedChemECellLine:PC-3,MGC-803Concentration:0.5μM,1μM,2μMIncubationTime:48hResult:Inhibitedinvasioninadose-dependentmanner.WesternBlotAnalysis[1]CellLine:PC-3,MGC-803Concentration:2.5μM,5μM,10μMIncubationTime:0-48hResult:InhibitedtheproteinlevelsofSkp2inadose-dependentmanner,restoredtheexpressionofp21andp27inatime-dependentmanner.體內(nèi)研究Skp2inhibitor1(50mg/kg,intraperitonealinjection/2day,21days)inhibitstumorgrowthsignificantlyinNOD-SCIDxenograftmodelswithoutobvioustoxicity.Inaddition,thetumortreatedwithSkp2inhibitor1(50mg/Kg/2day)wascompletelysuppressedinvivo[1].Skp2inhibitor1decreasestumormalignancyviasuppressingtheSkp2signalpathwayandincreasetheproportionofapoptosisinthetumortissue[1].PharmacokineticParametersofCompound14iinthePlasmaandTumorTissue[1]藥代動(dòng)力學(xué)分析[1]PKparametersplasmatumortissuet1/214.1±1.5(h)12.6±7.8(h)Cmax176.1±30.3(ng/mL)182.0±80.9(ng/g)AUClast3231.5±407.2(h.ng/mL)2443.9±474.9(h.ng/g)AUCINF3551.5±465.3(h.ng/mL)2636.0±619.7(h.ng/g)VZ143.3±9.2(L/kg)170.8±80.1(mg/kg)CL7.1±0.8(L/h/kg)15.7±4.2(mg/h/kg)MRTlast13.4±0.64(h)9.9±2.5(h)t1/2of14iintheLiverMicrosomesandLiverS9ofDifferentSpecies[1]體外代謝分析[1]specieshumanratmouset1/2livermicrosomes66.016.315.3t1/2liverS964.815.416.5AnimalModel:ThexenograftmodelsofPC-3andMGC-803cellsinNOD-SCIDmice[1].Dosage:10mg/kg;25mg/kg,50mg/kgAdministration:Intraperitonealinjection(i.p.)Result:Inhibitedtumorgrowthwithoutobvioustoxicity,thetumorgrowthinhibitionratiowas55.68,71.86,and90.42%with10,25,and50mg/Kg/2day,respectively.REFERENCES3/4 MasterofBioactiveMolecules—您身邊的抑制劑大師www.MedChemEZhangK,etal.DiscoveryofNovel1,3-DiphenylpyrazineDerivativesasPotentS-PhaseKinase-AssociatedProtein2(Skp2)InhibitorsfortheTreatmentofCancer.JMedChem.2023Jun8;66(11):7221-7

溫馨提示

  • 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。

評(píng)論

0/150

提交評(píng)論